tetano
Editor, Senior Moderator
Ann Intern Med
. 2021 Feb 9.
doi: 10.7326/M20-8148. Online ahead of print.
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Anjum S Kaka[SUP] 1 [/SUP], Roderick MacDonald[SUP] 2 [/SUP], Nancy Greer[SUP] 2 [/SUP], Kathryn Vela[SUP] 3 [/SUP], Wei Duan-Porter[SUP] 1 [/SUP], Adam Obley[SUP] 3 [/SUP], Timothy J Wilt[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19).
Purpose: To update a previous review of remdesivir for adults with COVID-19, including new meta-analyses of patients with COVID-19 of any severity compared with control.
Data sources: Several sources from 1 January 2020 through 7 December 2020.
Study selection: English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19. New evidence is incorporated by using living review methods.
Data extraction: 1 reviewer abstracted data; a second reviewer verified the data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used.
Data synthesis: The update includes 5 RCTs, incorporating data from a new large RCT and the final results of a previous RCT. Compared with control, a 10-day course of remdesivir probably results in little to no reduction in mortality (risk ratio [RR], 0.93 [95% CI, 0.82 to 1.06]; 4 RCTs) but may result in a small reduction in the proportion of patients receiving mechanical ventilation (RR, 0.71 [CI, 0.56 to 0.90]; 3 RCTs). Remdesivir probably results in a moderate increase in the percentage of patients who recovered and a moderate decrease in serious adverse events and may result in a large reduction in time to recovery. Effect on hospital length of stay or percentage remaining hospitalized is mixed. Compared with a 10-day course for those not requiring ventilation at baseline, a 5-day course may reduce mortality, the need for ventilation, and serious adverse events while increasing the percentage of patients who recovered or clinically improved.
Limitation: Summarizing findings was challenging because of varying disease severity definitions and outcomes.
Conclusion: In hospitalized adults with COVID-19, remdesivir probably results in little to no mortality difference but probably improves the percentage recovered and reduces serious harms and may result in a small reduction in the proportion receiving ventilation. For patients not receiving ventilation, a 5-day course may provide greater benefits and fewer harms with lower drug costs than a 10-day course.
Primary funding source: U.S. Department of Veterans Affairs.
. 2021 Feb 9.
doi: 10.7326/M20-8148. Online ahead of print.
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Anjum S Kaka[SUP] 1 [/SUP], Roderick MacDonald[SUP] 2 [/SUP], Nancy Greer[SUP] 2 [/SUP], Kathryn Vela[SUP] 3 [/SUP], Wei Duan-Porter[SUP] 1 [/SUP], Adam Obley[SUP] 3 [/SUP], Timothy J Wilt[SUP] 1 [/SUP]
Affiliations
- PMID: 33560863
- DOI: 10.7326/M20-8148
Abstract
Background: Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19).
Purpose: To update a previous review of remdesivir for adults with COVID-19, including new meta-analyses of patients with COVID-19 of any severity compared with control.
Data sources: Several sources from 1 January 2020 through 7 December 2020.
Study selection: English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19. New evidence is incorporated by using living review methods.
Data extraction: 1 reviewer abstracted data; a second reviewer verified the data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used.
Data synthesis: The update includes 5 RCTs, incorporating data from a new large RCT and the final results of a previous RCT. Compared with control, a 10-day course of remdesivir probably results in little to no reduction in mortality (risk ratio [RR], 0.93 [95% CI, 0.82 to 1.06]; 4 RCTs) but may result in a small reduction in the proportion of patients receiving mechanical ventilation (RR, 0.71 [CI, 0.56 to 0.90]; 3 RCTs). Remdesivir probably results in a moderate increase in the percentage of patients who recovered and a moderate decrease in serious adverse events and may result in a large reduction in time to recovery. Effect on hospital length of stay or percentage remaining hospitalized is mixed. Compared with a 10-day course for those not requiring ventilation at baseline, a 5-day course may reduce mortality, the need for ventilation, and serious adverse events while increasing the percentage of patients who recovered or clinically improved.
Limitation: Summarizing findings was challenging because of varying disease severity definitions and outcomes.
Conclusion: In hospitalized adults with COVID-19, remdesivir probably results in little to no mortality difference but probably improves the percentage recovered and reduces serious harms and may result in a small reduction in the proportion receiving ventilation. For patients not receiving ventilation, a 5-day course may provide greater benefits and fewer harms with lower drug costs than a 10-day course.
Primary funding source: U.S. Department of Veterans Affairs.